homepage-top-section

Alder BioPharmaceuticals is involved in the discovery, development and commercialisation of novel therapeutic antibodies. As per terms of the deal, Lundbeck will begin a tender offer for all

The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m),

Neoleukin is involved in the creation of next-generation immunotherapies using de novo protein design technology. The company applies advanced computational methods for the designing of proteins, which show

Nucala, a pre-filled pen and a pre-filled safety syringe, is claimed to be the only monthly anti-IL5 biologic approved in Europe to treat patients with severe eosinophilic asthma

Mirdametinib, formerly PD-0325901, is an oral and small molecule inhibitor of MEK1 and MEK2. The company has already secured orphan drug designation from the US Food and Drug

The BBT-877 is Bridge Biotherapeutics’ autotaxin inhibitor being developed to treat various fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). Under the deal, Bridge Biotherapeutics will secure

The deal includes an upfront payment, and contingent clinical, development and regulatory milestone payments. AMAL Therapeutics is also eligible to receive up to €100m (£89.8m) based on the

The partnership will discontinue the evaluation of CNP520 in two pivotal phase II/III studies in the Alzheimer’s Prevention Initiative Generation Programme. According to Novartis, an evaluation of unblinded

According to the company, Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated to treat primary humoral immunodeficiency (PI) in patients